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Therefore, we investigated the effect of radiotherapy on 
Ledderhose disease. 
 
Material and Methods: Between 2008 and 2014, 37 patients 
(56 feet) with Ledderhose disease were treated with 
radiotherapy at our department (figure 1). Radiation 
treatment consisted of 30 Gy given in 10 fractions (orthovolt 
200 kV or electrons 6-10 MeV). After the first 5 fractions, a 8-
10 week split was included. After this split, the remaining 5 
fractions were given. Progressive disease (PD) was defined as 
progression of complaints. Stable disease (SD) was defined as 
no improvement or progression of complaints. Partial 
response (PR) was defined as improvement or no complaints, 
but still nodules were present. Complete response (CR)was 
defined as no complaints and no nodules present. 
 
Results: All patients completed the planned treatment. The 
mean follow-up time was 25 months (range 3 to 46 months). 
Mean age of patients was 53 years, 46% were men, 54% were 
women. In 51% of patients (n=19), both feet were affected. 
After the radiotherapy, a minority of the patients complained 
of rash or dry skin, which resolved spontaneously. Of the 56 
feet treated, 5% had PD, 23% had SD, 64% had PR and 7% had 
CR. No radiation induced malignancies were seen. Of the two 
patients with PD, one patient had previous surgery for 
Ledderhose disease and the other patient had PD disease 
after an initial PR. 
 
 
Conclusion: Radiotherapy is an effective treatment for 
Ledderhose disease. However, the National Health Care 
Institute of the Netherlands does not support radiotherapy 
for Ledderhose disease as no randomized controlled trail 
have investigated the efficacy of radiotherapy. Therefore, we 
will present a double blind randomized multicentre phase 
three study to confirm the current results prospectively. 
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Purpose or Objective: Nowadays stereotactic body 
radiotherapy (SBRT) is considered a safe and effective 
approach for several sites of metastatic disease. So far, few 
published data exist on local control rates of radiotherapy in 
the context of isolated or limited lymph node metastases. We 
analyzed the dosimetric and clinical results of 
oligometastatic patients treated with SBRT for isolated lymph 
node metastases in abdomen and/or pelvis. 
 
Material and Methods: In the analysis we included patients 
with a maximum of 3 lymph node sites of disease with 
diameter less than 5 cm, located in the abdomen or pelvis. 
Radiotherapy was administered with Volumetric Modulated 
Arc Therapy Rapid-Arc (VMAT-RA) and flattening filter-free 
(FFF) beams; prescribed dose was 45 Gy in 6 fractions of 7.5 
Gy each. We analyzed dosimetric data and correlated them 
with acute toxicity (CTCAE 3.0), local and distant control of 
disease, progression free survival and overall survival. 
 
Results: From January 2006 to May 2015, we treated 97 
patients with lymph node metastases, of which 26 were lost 
at follow-up. We analyzed then 71 patients with a total of 79 
treated lesions, with a mean follow-up of 1.44 years (range 
0.14 – 6.21 years). At revaluation, complete response was 
achieved in 39 (49.3%) lesions and partial response in 28 
(35.4%) lesions. Stable disease was demonstrated in 10 
(12.6%) cases while only 2 (2.5%) lesions showed progression 
of disease. The overall clinical benefit rate was 97.5% (77/79 
lesions). Acute toxicity was mild: 10 (14%) patients reported 
G1 toxicity (notably nausea and fatigue); 2 (2.8%) patients 
reported G2 toxicity (nausea and diarrhea). No Grade 3 and 4 
toxicities were reported. In-field progression of disease 
during follow-up was demonstrated in 18 sites (22.7%) with a 
median time of 10.7 months. Out-field lymph node 
progression was demonstrated in 22 (27.8%) cases while 
distant metastases occurred in 25 (31.6%) cases. Local control 
rate and overall survival rate at 1 year were 83% and 93%, 
respectively. 
 
Conclusion: In consideration of our dosimetric and clinical 
results, SBRT with VMAT-RA and FFF beams can be considered 
a safe and effective approach in oligometastatic patients 
with abdomino-pelvic isolated lymph node metastases. 
Although this can be considered an initial experience, these 
results may be potentially significant for preserving quality of 
life of patients and delaying further systemic treatments. 
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Purpose or Objective: The purpose of this study was to 
evaluate the efficacy and feasibility of carbon ion 
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radiotherapy(CIRT) for Oligo-metastatic tumors located 
different organ from various cancer. 
 
Material and Methods: From December 2009 to June 2013, 
17 patients joined into the clinical study as volunteers. The 
patients were not surgical candidates for medical reasons or 
patient refusal. The Oligometastases located in lung,brain 
and liver respectively from various cancer were treated with 
CIRT.The heavy ion beams energy was 230~350Mev / u and 
RBE value was 2.5. A median dose of 60 GyE (range, 20–66 
GyE) was delivered to the planning target volume (PTV) in 4-
12 fractions with a median daily dose of 5 GyE (range, 4.68–
5.5 GyE). Short-term effect was evaluated by tumor change 
in three months after treatment with RESIST criteria and 
adverse reactions were determined by criteria of acute 
radiation injury from Radiation Therapy Oncology Group. 
Treatment outcome was analyzed in terms of local control 
rate(LCR), survival rate. 
 
Results: In total, 17 patients (7 lung Oligometastases, 3 liver 
Oligometastases and 7 brain Oligometastases)with 17 Oligo-
metastatic lesions were treated with CIRT. Until December 
2014, median follow-up period was 18 months(2-40ms). 
Objective response rate was 94.1% to evaluate short-term 
effect (3CR, 10PR, 3NC, 1PD) .The 1-year LCR and overall 
survival of the treated patients were 93.3% and 51.0%. Only 1 
lung Oligometastases patients relapsed in 7 months after 
treatment. 1-year Survival rate were 47.6%,66.7%, 75% 
respectively in brain, lung and liver Oligometastases. Survival 
rate and LCR were not significantly correlated with 
Oligometastases location. All treatment-related 
complications were acute skin reaction and self-limited, 
without any grade 4–5 toxicity. 
 
Conclusion: ompared with Conventional radiotherapy, CIRT 
has short treatment time, high Biological effect advantages. 
CIRT may be one of effective, the least invasive and safe 
approach to patients with Oligometastases. 
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Purpose or Objective: This study summarizes the experience 
with carbon ion radiation therapy (RT) at the Heavy Ion 
Research Facility in Lanzhou since 2009. 
 
Material and Methods: From December 2009 to June 2013, 
60 patients joined into the clinical study as volunteers. 14 
patients with brain tumor〔cerebral glioma(n=6), metastatic 
brain tumor (n=8)〕,8 patients with head and neck tumor,15 
patients with chest tumor〔primary lung cancer (n=8), 
metastatic mediastinal carcinoma(n=1), metastatic lung 
cancer(n=6)〕,13 patients with abdominal 
carcinoma〔primary liver cancer(n=4), pancreatic 
cancer(n=1), abdominal soft tissue malignant tumor (n=3), 
metastatic liver cancer(n=4), abdominal lymph node 
metastasis carcinoma(n=1)〕,5 patients with pelvic 
tumor〔rectal cancer(n=1), anal cancer (n=1), ovarian 
carcinoma(n=1), chordoma(n=1), soft tissue tumor(n=1)〕,5 
patients with limbs tumor〔skin cancer(n=2), soft tissue 
malignant tumor(n=3)〕were treated with carbon ions beams. 
The beams energy was 230~350Mev / u and RBE value was 
2.5. A median dose of 60 GyE (range, 20–66 GyE) was 
delivered to the planning target volume (PTV) in 4-12 
fractions with a median daily dose of 5 GyE (range, 4.68–5.5 
GyE). Short-term effect was evaluated by tumor change in 
three months after treatment with RESIST criteria and 
adverse reactions were determined by criteria of acute 
radiation injury from Radiation Therapy Oncology Group. 
Treatment outcome was analyzed in terms of local control 
rate (LCR), survival rate. 
 
Results: Until December 2014, median follow-up period was 
18 months (2-40ms). Objective response rate was 98.3% to 
evaluate short-term effect (9CR, 37PR, 13NC, 1PD) .The 1-
year LCR and overall survival of the treated patients were 
80.2% and 62.8%. The local control and overall survival rates 
were not correlated with tumor location and pathological 
types, the main cause of death was distant metastasis. All 
treatment related complications were 1-2 grade acute skin 
reaction (incidence rate = 66.7%) and self-limited, without 
any grade 4–5 toxicity. 
 
Conclusion: Carbon ion therapy is safe with respect to 
toxicity , offers high tumor local control rates and 
significantly shorten the treatment time. But this study has 
limitations: a group of cancer patients in advanced stage and 
short survival and follow up time, small sample size and high 
heterogeneity because of tumor location, clinical stage and 
pathological type. More homogeneous prospective data, large 
multicentric and randomized trials are needed to evaluate 
the efficacy of heavy ion tumor therapy. 
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Purpose or Objective: Although radiation therapy (RT) is 
widely used in orbital tumors, the clinical use of ophthalmic 
RT has not been established in the lack of prospective data. 
This study evaluated the single institution’s patterns of care 
and treatment outcomes of RT in non-metastatic primary 
tumors and inflammatory diseases in the eye and orbit. 
 
Material and Methods: We retrospectively reviewed a total 
of 138 patients and 147 treatments of primary orbital 
malignancies or inflammatory conditions from January 2000 
to December 2013. The aims of RT consisted of definitive 
(n=121), postoperative (n=16), palliative (n=6), and salvage 
(n=4) treatment. Retrobulbar (34%) and conjunctival (22%) 
area were the common subsites of treatment. The median 
external beam RT dose was 30.6 Gy (range, 10.0-66.6) with a 
daily fraction size ranging from 1.7 to 4.0 Gy. Three-
dimensional conformal and intensity-modulated techniques 
were delivered in 67 (46%) and 5 (3%) treatments, 
respectively. 
 
Results: Forty-eight (35%) patients had benign inflammatory 
diseases including thyroid-associated ophthalmopathy (n=24), 
inflammatory pseudotumor (n=13), and choroidal neovascular 
membranes (n=11). In 90 (65%) patients with malignant 
tumors, 13 (9%) patients were children diagnosed with 
retinoblastoma (n=7), optic glioma (n=4), optic meningioma 
(n=1), and ocular teratoid medulloepithelioma (n=1). The 
other 77 (56%) patients were adult with the 5-year overall 
survival rate of 78.3%. Among the non-pediatric patients, 
mucosa-associated lymphoid tissue (MALT) lymphoma (n=36) 
was the most frequent disease entity, and the others also 
included optic meningioma (n=6), melanoma (n=5), and 
adenoid cystic carcinoma (n=5). In a total of 81 adult 
malignant tumors, complete and partial responses were 
observed in 67 (83%) tumors, and the patients’ 5-year 
relapse-free survival was 60.8%. In the 42 treatments of TAO 
and inflammatory pseudotumor, inflammatory symptoms 
were improved in 57%. There were 58 (39%) events of acute 
toxicities, and grade 1-2 ocular discomfort (n=18) and nausea 
(n=9) were frequent. Among the 24 (16%) events of late 
toxicities, 10 (42%) and 2 (8%) events of radiation-induced 
cataract and retinopathy were observed, respectively. Grade 
≥3 toxicities were not reported. 
 
Conclusion: In current practices, the ophthalmic RT achieved 
an excellent treatment response and tumor control with 
tolerable short-term and long-term toxicities. Further 
